Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients.
Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients.
复制标题
DOI：
10.1517/14740338.4.6.1051
复制
发表时间：
2005-11-01
影响因子：
3.1
通讯作者：
Gridelli, Cesare
中科院分区：
文献类型：
--
作者：
Rossi, Antonio;Maione, Paolo;Gridelli, Cesare
非小细胞肺癌（NSCLC）可能被认为是高龄癌症的典型表现。超过 50% 的 NSCLC 患者在 > 65 岁时被诊断出来，大约三分之一的患者年龄 > 70 岁。与年轻患者相比，老年患者对化疗的耐受性较差，因为器官功能逐渐下降以及与年龄相关的合并症。因此，这些患者通常不适合接受积极的铂类化疗，这是晚期非小细胞肺癌的标准治疗方法。在临床实践中，单药化疗仍应是标准治疗方法。铂类化疗的可行性仍然是一个悬而未决的问题，必须进行前瞻性证明。此外，对于 NSCLC 老年患者的个体化治疗选择，必须进行多维老年评估。本综述的重点是关于铂类化疗的作用和安全性的晚期非小细胞肺癌老年患者治疗的现有证据。
Non-small cell lung cancer (NSCLC) may be considered typical of advanced age. More than 50% of NSCLC patients are diagnosed at > 65 years of age and approximately one-third of all patients are > 70 years of age. Elderly patients tolerate chemotherapy poorly compared with their younger counterpart because of the progressive reduction of organ function and comorbidities related to age. For this reason, these patients are often not considered eligible for aggressive platinum-based chemotherapy, the standard medical treatment for advanced NSCLC. In clinical practice, single-agent chemotherapy should remain the standard treatment. Feasibility of platinum-based chemotherapy remains an open issue and has to be proven prospectively. Moreover, a multidimensional geriatric assessment for individualised treatment choice in NSCLC elderly patients is mandatory. This review focuses on the currently-available evidences for the treatment of elderly patients affected by advanced NSCLC with regards to the role and safety of platinum-based chemotherapy.